







PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 31/5365, C07D 498/04, 519/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/64449 (43) International Publication Date: 2 November 2000 (02.11.00)</p>
<p>(21) International Application Number: PCT/US00/10521 (22) International Filing Date: 19 April 2000 (19.04.00) (30) Priority Data: 60/130,670 23 April 1999 (23.04.99) US (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COBURN, Craig [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). VACCA, Joseph, P. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: THROMBIN INHIBITORS</p> <div style="text-align: center;">  <p>(I)</p> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;">  <p>(a)</p> </div> <div style="text-align: center;">  <p>(b)</p> </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;">  <p>(c)</p> </div> <div style="text-align: center;">  <p>(d)</p> </div> <div style="text-align: center;">  <p>(e)</p> </div> </div> <p>(57) Abstract</p> <p>Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have structure: (I) or a pharmaceutically acceptable salt thereof, wherein A is (a), (b), (c), (d), or (e).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION
THROMBIN INHIBITORS

BACKGROUND OF THE INVENTION

5 Thrombin is a serine protease present in blood plasma in the form of a precursor, prothrombin. Thrombin plays a central role in the mechanism of blood coagulation by converting the solution plasma protein, fibrinogen, into insoluble fibrin.

 Edwards *et al.*, *J. Amer. Chem. Soc.*, (1992) vol. 114, pp. 1854-63,
10 describes peptidyl α -ketobenzoxazoles which are reversible inhibitors of the serine proteases human leukocyte elastase and porcine pancreatic elastase.

 European Publication 363 284 describes analogs of peptidase substrates in which the nitrogen atom of the scissile amide group of the substrate peptide has been replaced by hydrogen or a substituted carbonyl moiety.

15 Australian Publication 86245677 also describes peptidase inhibitors having an activated electrophilic ketone moiety such as fluoromethylene ketone or α -keto carboxyl derivatives.

 R. J. Brown *et al.*, *J. Med. Chem.*, Vol. 37, pages 1259-1261 (1994) describes orally active, non-peptidic inhibitors of human leukocyte elastase which
20 contain trifluoromethylketone and pyridinone moieties.

 H. Mack *et al.*, *J. Enzyme Inhibition*, Vol. 9, pages 73-86 (1995) describes rigid amidino-phenylalanine thrombin inhibitors which contain a pyridinone moiety as a central core structure.

25 SUMMARY OF THE INVENTION

 The invention includes compounds for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.

30 These compounds may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents. The compounds can be added to blood, blood products, or mammalian organs in order to effect the desired inhibitions.


 The invention also includes a compound for preventing or treating unstable angina, refractory angina, myocardial infarction, transient ischemic attacks,
35 atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis,

disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels, in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. These compounds may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.





- 5 The invention also includes a method for reducing the thrombogenicity of a surface in a mammal by attaching to the surface, either covalently or noncovalently, a compound of the invention.

10 DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS


Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure:



- 15 or a pharmaceutically acceptable salt thereof,
wherein A is



, or



R^5 is hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, halogen, NH_2 , OH or C_{1-4} alkoxy;

20

R^4 is hydrogen, Cl, F, C_{1-4} alkyl or NH_2 ;

Y is hydrogen, Cl, or F;

R¹ and R² are independently

hydrogen,

5 phenyl, unsubstituted or substituted with one or more of C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂, CH₂OH, CO₂R⁸, where R⁸ is C₁₋₄ alkyl, or SO₂NH₂,
CHR⁶R⁷

wherein R⁶ and R⁷ are independently

10 hydrogen,

unsubstituted C₁₋₄ alkyl,

C₁₋₄ alkyl substituted with OH, COOH, NH₂, aryl, CF₃,

C₃₋₇ cycloalkyl,

CF₃

15 CH₂C₃₋₇ cycloalkyl, unsubstituted or substituted with aryl,


C₇₋₁₂ bicyclic alkyl, or

C₁₀₋₁₆ tricyclic alkyl; and


R⁹ is C₁₋₄ alkyl or SO₂NH₂.

20 A class of compounds of the invention, or a pharmaceutically acceptable salt thereof, includes those wherein R⁴ is Cl, R⁵ is hydrogen and Y is hydrogen.

A group of this class of compounds, or a pharmaceutically acceptable salt thereof, includes those wherein A is



5 R^1 and R^2 are independently
 $-\text{CH}_3$,
 $-\text{CH}_2\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}_2\text{CH}_3$,
 $-\text{CH}(\text{CH}_3)_2$, or



10 R^9 is CH_3 .

15 Examples of this group are listed below in Table 1. Inhibitory activity of compounds of the invention is represented by "**", indicating K_i greater than or equal to 100 nM, or "*", indicating K_i less than 100 nM. Values are as determined according to the in vitro assay described later in the specification.

Table 1







Table 1 (continued)



5 The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. The compounds of the present invention may also have polymorphic crystalline forms, with all polymorphic crystalline forms being included in the present invention.

The invention also includes compounds having the following structure:



10

which are useful for preparing thrombin inhibitors, wherein

R¹ and R² are independently

hydrogen,

phenyl, unsubstituted or substituted with one or more of C₁₋₄

alkyl, C₁₋₄ alkoxy, halogen, hydroxy, COOH, CONH₂, CH₂OH,
CO₂R⁸, where R⁸ is C₁₋₄ alkyl, or SO₂NH₂,
CHR⁶R⁷

wherein R⁶ and R⁷ are independently

- 5 hydrogen,
 unsubstituted C₁₋₄ alkyl,
 C₁₋₄ alkyl substituted with OH, COOH, NH₂, aryl, CF₃,
 C₃₋₇ cycloalkyl,
 CF₃
10 CH₂C₃₋₇ cycloalkyl, unsubstituted or substituted with aryl,
 C₇₋₁₂ bicyclic alkyl, or
 C₁₀₋₁₆ tricyclic alkyl.

When any variable occurs more than one time in any constituent or in
formula I, its definition on each occurrence is independent of its definition at every
15 other occurrence. Also, combinations of substituents and/or variables are permissible
only if such combinations result in stable compounds.

As used herein except where noted, "alkyl" is intended to include both
branched- and straight-chain saturated aliphatic hydrocarbon groups having the
specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl);
20 "alkoxy" represents a linear or branched alkyl group of indicated number of carbon
atoms attached through an oxygen bridge; "Halo", as used herein, means fluoro,
chloro, bromo and iodo; and "counterion" is used to represent a small, single
negatively-charged species, such as chloride, bromide, hydroxide, acetate,
trifluoroacetate, perchlorate, nitrate, benzoate, maleate, sulfate, tartrate, hemitartrate,
25 benzene sulfonate, and the like.

The term "C₃₋₇cycloalkyl" is intended to include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like.

The term "C₇₋₁₂ bicyclic alkyl" is intended to include
bicyclo[2.2.1]heptyl (norbornyl), bicyclo[2.2.2]octyl, 1,1,3-trimethyl-
30 bicyclo[2.2.1]heptyl (bornyl), and the like.

The term "aryl" as used herein except where noted, represents a stable
6- to 10-membered mono- or bicyclic ring system. The aryl ring can be unsubstituted
or substituted with one or more of C₁₋₄ lower alkyl; hydroxy; alkoxy; halogen;
amino. Examples of "aryl" groups include phenyl and naphthyl.

The term "heterocycle" or "heterocyclic ring", as used herein except where noted, represents a stable 5- to 7-membered mono- or bicyclic or stable 9- to 10-membered bicyclic heterocyclic ring system any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. Bicyclic unsaturated ring systems include bicyclic ring systems which may be partially unsaturated or fully unsaturated. Partially unsaturated bicyclic ring systems include, for example, cyclopentenopyridinyl, benzodioxan, methylenedioxyphenyl groups. Especially useful are rings containing one oxygen or sulfur, one to four nitrogen atoms, or one oxygen or sulfur combined with one or two nitrogen atoms. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic groups include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiophenyl, oxazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, tetrazole, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the same as morpholinyl. Unsaturated heterocyclic rings may also be referred to hereinafter as "heteroaryl" rings.

The pharmaceutically-acceptable salts of the compounds of Formula I (in the form of water- or oil-soluble or dispersible products) include the conventional non-toxic salts such as those derived from inorganic acids, e.g. hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases. Examples of acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate,

maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, tosylate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth

5 metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl;

10 and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.

Some abbreviations that may appear in this application are as follows:

15

ABBREVIATIONS

Designation

BOC (Boc)

CBZ (Cbz)

TBS (TBDMS)

Protecting Group

t-butyloxycarbonyl

benzyloxycarbonyl(carbobenzoxym)

t-butyl-dimethylsilyl

Activating Group

HBT(HOBT or HOBt)

1-hydroxybenzotriazole hydrate

Designation

BOP reagent

BOP-Cl

EDC

Coupling Reagent

benzotriazol-1-yloxytris-

(dimethylamino)phosphonium

hexafluorophosphate

bis(2-oxo-3-oxazolidinyl)phosphinic chloric

1-ethyl-3-(3-dimethylaminopropyl)

carbodiimide hydrochloride

Other

(BOC)₂O (BOC₂O)

di-t-butyl dicarbonate

n-Bu₄N⁺F⁻

tetrabutyl ammonium fluoride

nBuLi (n-Buli)	n-butyllithium
DMF	dimethylformamide
Et ₃ N (TEA)	triethylamine
EtOAc	ethyl acetate
TFA	trifluoroacetic acid
DMAP	dimethylaminopyridine
DME	dimethoxyethane
NMM	N-methylmorpholine
DPPA	diphenylphosphoryl azide
THF	tetrahydrofuran
DIPEA	diisopropylethylamine

Amino Acid

Ile	Isoleucine
Phe	Phenylalanine
Pro	Proline
Ala	Alanine
Val	Valine

In vitro assay for determining proteinase inhibition

Assays of human α -thrombin and human trypsin were performed by the methods substantially as described in *Thrombosis Research*, Issue No. 70, page 173 (1993) by S.D. Lewis *et al.*

The assays were carried out at 25°C in 0.05 M TRIS buffer pH 7.4, 0.15 M NaCl, 0.1% PEG. Trypsin assays also contained 1 mM CaCl₂. In assays wherein rates of hydrolysis of a *p*-nitroanilide (pna) substrate were determined, a Thermomax 96-well plate reader was used to measure (at 405 nm) the time dependent appearance of *p*-nitroaniline. sar-PR-pna was used to assay human α -thrombin ($K_m=125 \mu M$) and bovine trypsin ($K_m=125 \mu M$). *p*-Nitroanilide substrate concentration was determined from measurements of absorbance at 342 nm using an extinction coefficient of 8270 cm⁻¹M⁻¹.

In certain studies with potent inhibitors ($K_i < 10$ nM) where the degree of inhibition of thrombin was high, a more sensitive activity assay was employed. In this assay the rate of thrombin catalyzed hydrolysis of the fluorogenic substrate Z-

GPR-afc ($K_M=27 \mu M$) was determined from the increase in fluorescence at 500 nm (excitation at 400 nm) associated with production of 7-amino-4-trifluoromethyl coumarin. Concentrations of stock solutions of Z-GPR-afc were determined from measurements of absorbance at 380 nm of the 7-amino-4-trifluoromethyl coumarin produced upon complete hydrolysis of an aliquot of the stock solution by thrombin.

Activity assays were performed by diluting a stock solution of substrate at least tenfold to a final concentration $= 0.1 K_M$ into a solution containing enzyme or enzyme equilibrated with inhibitor. Times required to achieve equilibration between enzyme and inhibitor were determined in control experiments. Initial velocities of product formation in the absence (V_O) or presence of inhibitor (V_i) were measured. Assuming competitive inhibition, and that unity is negligible compared $K_M/[S]$, $[I]/e$, and $[I]/e$ (where $[S]$, $[I]$, and e respectively represent the total concentrations, of substrate, inhibitor and enzyme), the equilibrium constant (K_i) for dissociation of the inhibitor from the enzyme can be obtained from the dependence of V_O/V_i on $[I]$ shown in equation 1: $V_O/V_i = 1 + [I]/K_i$ (1).

The activities shown by this assay indicate that the compounds of the invention are therapeutically useful for treating various conditions in patients suffering from unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, and reocclusion or restenosis of recanalized vessels. The compounds of the invention are selective compounds, as evidenced by their inhibitory activity against human trypsin (represented by K_i).

Thrombin Inhibitors - Therapeutic Uses- Method of Using

Anticoagulant therapy is indicated for the treatment and prevention of a variety of thrombotic conditions, particularly coronary artery and cerebrovascular disease. Those experienced in this field are readily aware of the circumstances requiring anticoagulant therapy. The term "patient" used herein is taken to mean mammals such as primates, including humans, sheep, horses, cattle, pigs, dogs, cats, rats, and mice.

Thrombin inhibition is useful not only in the anticoagulant therapy of individuals having thrombotic conditions, but is useful whenever inhibition of blood coagulation is required such as to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, the

thrombin inhibitors can be added to or contacted with any medium containing or suspected of containing thrombin and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material selected from the group consisting of vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis,
5 and extracorporeal circulation systems.

Compounds of the invention are useful for treating or preventing venous thromboembolism (e.g. obstruction or occlusion of a vein by a detached thrombus; obstruction or occlusion of a lung artery by a detached thrombus), cardiogenic thromboembolism (e.g. obstruction or occlusion of the heart by a
10 detached thrombus), arterial thrombosis (e.g. formation of a thrombus within an artery that may cause infarction of tissue supplied by the artery), atherosclerosis (e.g. arteriosclerosis characterized by irregularly distributed lipid deposits) in mammals, and for lowering the propensity of devices that come into contact with blood to clot blood.

15 Examples of venous thromboembolism which may be treated or prevented with compounds of the invention include obstruction of a vein, obstruction of a lung artery (pulmonary embolism), deep vein thrombosis, thrombosis associated with cancer and cancer chemotherapy, thrombosis inherited with thrombophilic diseases such as Protein C deficiency, Protein S deficiency, antithrombin III
20 deficiency, and Factor V Leiden, and thrombosis resulting from acquired thrombophilic disorders such as systemic lupus erythematosus (inflammatory connective tissue disease). Also with regard to venous thromboembolism, compounds of the invention are useful for maintaining patency of indwelling catheters.

Examples of cardiogenic thromboembolism which may be treated or
25 prevented with compounds of the invention include thromboembolic stroke (detached thrombus causing neurological affliction related to impaired cerebral blood supply), cardiogenic thromboembolism associated with atrial fibrillation (rapid, irregular twitching of upper heart chamber muscular fibrils), cardiogenic thromboembolism associated with prosthetic heart valves such as mechanical heart valves, and
30 cardiogenic thromboembolism associated with heart disease.

Examples of arterial thrombosis include unstable angina (severe constrictive pain in chest of coronary origin), myocardial infarction (heart muscle cell death resulting from insufficient blood supply), ischemic heart disease (local anemia due to obstruction (such as by arterial narrowing) of blood supply), reocclusion during
35 or after percutaneous transluminal coronary angioplasty, restenosis after percutaneous

transluminal coronary angioplasty, occlusion of coronary artery bypass grafts, and occlusive cerebrovascular disease. Also with regard to arterial thrombosis, compounds of the invention are useful for maintaining patency in arteriovenous cannulas.

5 Examples of atherosclerosis include arteriosclerosis.

 Examples of devices that come into contact with blood include vascular grafts, stents, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems

 The thrombin inhibitors of the invention can be administered in such
10 oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-
15 toxic amount of the compound desired can be employed as an anti-aggregation agent. For treating ocular build up of fibrin, the compounds may be administered intraocularly or topically as well as orally or parenterally.

 The thrombin inhibitors can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to
20 permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

25 The thrombin inhibitors can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

 Prodrugs of described compounds are compound derivatives which,
30 when absorbed into the bloodstream of a warm-blooded animal, cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy. The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible *in vivo* into the required
35 compound. Thus, in the methods of treatment of the present invention, the term

"administering" shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound *in vivo* after administration to the patient. Conventional procedures for the selection and
5 preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.

The thrombin inhibitors may also be delivered by the use of
10 monoclonal antibodies as individual carriers to which the compound molecules are coupled. The thrombin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl
15 residues. Furthermore, the thrombin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block
20 copolymers of hydrogels.

The dosage regimen utilizing the thrombin inhibitors is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular
25 compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

Oral dosages of the thrombin inhibitors, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 30 mg/kg/day, preferably 0.025-7.5 mg/kg/day, more preferably 0.1-2.5
30 mg/kg/day, and most preferably 0.1-0.5 mg/kg/day (unless specified otherwise, amounts of active ingredients are on free base basis). For example, an 80 kg patient would receive between about 0.8 mg/day and 2.4 g/day, preferably 2-600 mg/day, more preferably 8-200 mg/day, and most preferably 8-40 mg/kg/day. A suitably
35 prepared medicament for once a day administration would thus contain between 0.8

mg and 2.4 g, preferably between 2 mg and 600 mg, more preferably between 8 mg and 200 mg, and most preferably 8 mg and 40 mg, e.g., 8 mg, 10 mg, 20 mg and 40 mg. Advantageously, the thrombin inhibitors may be administered in divided doses of two, three, or four times daily. For administration twice a day, a suitably prepared
5 medicament would contain between 0.4 mg and 4 g, preferably between 1 mg and 300 mg, more preferably between 4 mg and 100 mg, and most preferably 4 mg and 20 mg, e.g., 4 mg, 5 mg, 10 mg and 20 mg.

Intravenously, the patient would receive the active ingredient in quantities sufficient to deliver between 0.025-7.5 mg/kg/day, preferably 0.1-2.5
10 mg/kg/day, and more preferably 0.1-0.5 mg/kg/day. Such quantities may be administered in a number of suitable ways, e.g. large volumes of low concentrations of active ingredient during one extended period of time or several times a day, low volumes of high concentrations of active ingredient during a short period of time, e.g. once a day. Typically, a conventional intravenous formulation may be prepared which
15 contains a concentration of active ingredient of between about 0.01-1.0 mg/ml, e.g. 0.1 mg/ml, 0.3 mg/ml, and 0.6 mg/ml, and administered in amounts per day of between 0.01 ml/kg patient weight and 10.0 ml/kg patient weight, e.g. 0.1 ml/kg, 0.2 ml/kg, 0.5 ml/kg. In one example, an 80 kg patient, receiving 8 ml twice a day of an intravenous formulation having a concentration of active ingredient of 0.5 mg/ml,
20 receives 8 mg of active ingredient per day. Glucuronic acid, L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be used as buffers. Consideration should be given to the solubility of the drug in choosing an The choice of appropriate buffer and pH of a formulation, depending on
25 solubility of the drug to be administered, is readily made by a person having ordinary skill in the art.

The compounds can also be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be
30 administered in the form of a transdermal delivery system, the dosage administration will, or course, be continuous rather than intermittent throughout the dosage regime.

The thrombin inhibitors are typically administered as active ingredients in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier" materials) suitably selected with respect to the intended

form of administration, that is, oral tablets, capsules, elixers, syrups and the like, and consistent with convention pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch methyl cellulose, agar, bentonite, xanthan gum and the like.

Typical uncoated tablet cores suitable for administration of thrombin inhibitors are comprised of, but not limited to, the following amounts of standard ingredients:

Excipient	General Range (%)	Preferred Range (%)	Most Preferred Range (%)
mannitol	10-90	25-75	30-60
microcrystalline cellulose	10-90	25-75	30-60
magnesium stearate	0.1-5.0	0.1-2.5	0.5-1.5

Mannitol, microcrystalline cellulose and magnesium stearate may be substituted with alternative pharmaceutically acceptable excipients.

The thrombin inhibitors can also be co-administered with suitable anti-platelet agents, including, but not limited to, fibrinogen receptor antagonists (e.g. to treat or prevent unstable angina or to prevent reocclusion after angioplasty and restenosis), anticoagulants such as aspirin, thrombolytic agents such as plasminogen


activators or streptokinase to achieve synergistic effects in the treatment of various vascular pathologies, or lipid lowering agents including antihypercholesterolemics (e.g. HMG CoA reductase inhibitors such as lovastatin, HMG CoA synthase inhibitors, etc.) to treat or prevent atherosclerosis. For example, patients suffering from coronary artery disease, and patients subjected to angioplasty procedures, would benefit from coadministration of fibrinogen receptor antagonists and thrombin inhibitors. Also, thrombin inhibitors enhance the efficiency of tissue plasminogen activator-mediated thrombolytic reperfusion. Thrombin inhibitors may be administered first following thrombus formation, and tissue plasminogen activator or other plasminogen activator is administered thereafter.

Typical doses of thrombin inhibitors of the invention in combination with other suitable anti-platelet agents, anticoagulation agents, or thrombolytic agents may be the same as those doses of thrombin inhibitors administered without coadministration of additional anti-platelet agents, anticoagulation agents, or thrombolytic agents, or may be substantially less than those doses of thrombin inhibitors administered without coadministration of additional anti-platelet agents, anticoagulation agents, or thrombolytic agents, depending on a patient's therapeutic needs.


General procedure for making compounds of the invention

Compounds may be prepared, for example, by a common condensation reaction between a group having a carboxylic acid moiety and a group having an amino moiety, forming a peptide or amide bond. Compounds may be prepared by other means however, and suggested starting materials and procedures described below are exemplary only and should not be construed as limiting the scope of the invention.

In general, compounds having the general structure




wherein the variables have the above-described meanings, can be prepared by reacting



with $\text{H}_2\text{NCH}_2\text{A}$ under conditions suitable for forming amide bond between the acid and the amine.



Suitable carboxylic acid starting materials for




5

may be prepared according to the following procedures.

General synthesis



10



$\text{H}_2\text{NCH}_2\text{A}$ can be, for example, aminopyridine (see WO 99/11267 for preparation) and related amino derivatives, 3-chlorobenzylamine (commercially

available from Aldrich), or azaindoles such as those prepared according to the following procedure:

Amides of 5-aminomethyl-7-azaindole

5 Following Van Der Plas et al., *Tetrahedron* 1989,45, 803, and Taylor et al. *ibid.* 1987, 43, 5145. NBS (2.71 g, 15.2 mmol) was added to a stirred solution of 7-azaindoline (1.83 g, 15.2 mmol, in chloroform (200 mL). After 1 h, the reaction mixture was washed with 10% sodium metabisulfite solution, dried (Na₂SO₄), filtered through a pad of silica (eluting with ethyl acetate) and evaporated *in vacuo* to give 7-aza-5-bromoindoline:

¹H NMR (CDCl₃) δ 3.09 (t, J = 8.5 Hz, 2H), 3.74 (t, J = 8.5 Hz, 2H), 5.00 (br s, 1H), 7.32 (s, 1H), 8.13 (s, 1H).

 A stirred mixture of 7-aza-5-bromoindole (171 mg, 0.86 mmol), zinc cyanide (61 mg, 0.52 mmol) and tetrakis(triphenyl-phosphine)palladium (0) (60 mg, 0.052 mmol) in DMF (1 mL) was heated to 80° C under argon. After 5 h, the reaction mixture was partitioned between methylene chloride and water. The organic layer was dried (MgSO₄) and evaporated *in vacuo*. The crude product was purified by flash column chromatography on silica (80% ethyl acetate/hexanes) to give 7-aza-5-cyanoindoline:

20 ¹H NMR (CDCl₃) δ 3.07 (m, 2H), 3.65 (t, J = 8.4 Hz, 2H), 4.52 (br s, 1H), 7.31 (s, 1H), 7.85 (s, 1H).


 A suspension of 7-aza-5-cyanoindoline (98 mg, 0.68 mmol) and 10% palladium on carbon (50 mg) in methanol (10 mL) and 6 M HCl (1 mL) was shaken on a Parr apparatus under hydrogen (55 psi) for 16 h. The mixture was filtered through celite and evaporated *in vacuo* to give 5-aminomethyl-7-azaindoline dihydrochloride:

25 ¹H NMR (CDI₃OD) δ 3.30 (obscured t, 2H), 3.95 (t, J = 8.2 Hz, 2H), 4.03 (s, 2H), 7.66 (s, 2H).

30 Typically, solution phase amide couplings may be used to form the final product, but solid-phase synthesis by classical Merrifield techniques may be employed instead. The addition and removal of one or more protecting groups is also typical practice.

 Modifications of the method will allow different R¹, R², and A groups contemplated by the scope of the broad claim below to be present by the use of an


appropriate reagent or appropriately substituted starting material in the indicated synthetic step. Amino alcohols having different R1 and R2 groups can be prepared, for example, by a procedure such as the one below:



5

EXAMPLE 1

Step A: Ethyl 6-Methyl-3-Nitropyridone 4-Carboxylate




10

To a slurry nitroacetamide ammonia salt (70.3 g, 581 mmol) in 400 mL of deionized water was added 100 g (633 mmol, 1.09 equiv.) of ethyl 2,4-dioxovalerate followed by a solution of piperdinium acetate (prepared by adding 36 mL of piperdine to 21 mL of acetic acid in 100 mL of water). The resulting solution was stirred at 40°C for 16 h then cooled in an ice bath. The precipitated product was filtered and washed with 50 mL of cold water to give the above pyridone 1-1 as a yellow solid.

¹H NMR (CDCl₃) δ 6.43 (s, 1H), 4.35 (q, J=7 Hz, 2H), 2.40 (s, 3H), 1.35 (t, J=7 Hz, 3H).

10


Step B: Ethyl 2-Methoxy-6-Methyl-3-Nitropyridine 4-Carboxylate



A solution of the pyridone 1-1 from step A (6.2 g, 27.4 mmol) in 50 mL of DCM was treated with 4.47 g (30.2 mmol) of solid trimethyloxonium tetrafluoroborate and the mixture was stirred at 40°C until the reaction was judged to be complete by HPLC (typically 24-72 h). The reaction mixture was concentrated to one-third volume, loaded onto a silica gel column and eluted with 2:3 EtOAc/Hexane to give the methoxy pyridine 1-2 as a yellow liquid.


¹H NMR (CDCl₃) δ 7.2 (s, 1H), 4.35 (q, J=7 Hz, 2H), 4.05 (s, 3H), 2.55 (s, 3H), 1.35 (t, J=7 Hz, 3H).

Step C: Ethyl 3-Amino-2-Methoxy-6-Methylpyridine 4-Carboxylate




To an oxygen free solution of the nitro ester 1-2 from step B (2.5 g, 10.4 mmol) in 50 mL of EtOAc was added 520 mg of 10% Pd on charcoal. Hydrogen gas was added and the reaction mixture was stirred for 17h. The solution was filtered
5 through a pad of Celite, concentrated and chromatographed (2:3 EtOAc/Hexane) to give the desired amine 1-3 as a white solid.
¹H NMR (CDCl₃) δ 7.05 (s, 1H), 5.70 (bs, 2H), 4.35 (q, J=7 Hz, 2H), 3.95 (s, 3H), 2.37 (s, 3H), 1.39 (t, J=7 Hz, 3H).

10 Step D: Amino alcohol 1-4




To a -70°C solution of 260 mg (1.0 mmol) of the ester 1-3 from step C in 5 mL of THF was added 1.2 mL (3.5 mmol) of 3 M MeMgBr. The resulting
15 solution was allowed to warm to ambient temperature over 16 h. The reaction mixture was quenched with 5 mL of saturated NH₄Cl solution and the two phases were separated. The aqueous phase was extracted with 10 mL of EtOAc and the combined organic extracts were washed with 5 mL of brine and dried over MgSO₄.
The yellow solution was concentrated and chromatographed (1:1 EtOAc/Hexane) give
20 alcohol 1-4.
¹H NMR (CDCl₃) δ 6.45 (s, 1H), 4.60 (bs, 1H), 3.95 (s, 3H), 2.55 (s, 3H), 1.60 (s, 6H).

Step E: Oxazinone 1-5




To a solution of 386 mg (2.0 mmol) of the amino alcohol 1-4 from step
5 D in 10 mL of THF was added 1.62 g (10.0 mmol) of 1,1'-carbonyl diimidazole. The
resulting solution was heated at 55°C over 16 h. The reaction mixture was cooled and
the solvent was removed by rotory evaporation. The mixture was redissolved in 50
mL of EtOAc and washed sequentially with 10 mL each of saturated NH₄Cl solution,
water, then brine. The solution was concentrated and chromatographed (1:1
10 EtOAc/Hexane) to give oxazinone 1-5.
¹H NMR (CDCl₃) δ 7.17 (bs, 1H), 6.49 (s, 1H), 3.95 (s, 3H), 2.40 (s, 3H), 1.66 (s,
6H).


Step F: Pyridone 1-6



To 333 mg (1.5 mmol) of the oxazinone from step E was added 1.72 g
(15.0 mmol) of solid pyridine hydrochloride. The solid mixture was heated at 155°C
for 5 min to effect a melt. The reaction mixture was cooled to rt, quenched with 10
20 mL of water and stirred for 20 min. The resulting precipitate was filtered and air
dried to give pyridone 1-6.
¹H NMR (DMSO d₆) δ 11.85 (bs, 1H), 9.30 (bs, 1H), 6.03 (s, 1H), 2.10 (s, 3H), 1.45
(s, 6H).

Step G: Benzyl Ester 1-7


To 186 mg (0.89 mmol) of the pyridone 1-6 from step F in 5 mL of
5 DMF was added 325 mg (1.0 mmol) of Cs₂CO₃ and 0.158 mL (1.0 mmol) of benzyl
2-bromoacetate. The resulting mixture was stirred at rt for 15 h. The reaction mixture
was then evaporated to dryness, redissolved in 20 mL of EtOAc and washed with 3 x
5 mL of brine. The organic solution was dried over MgSO₄ concentrated and
chromatographed (EtOAc) to give benzyl ester 1-7.
10 ¹H NMR (CDCl₃) δ 7.45 (bs, 1H), 7.40 - 7.20 (m, 5H), 5.90 (s, 1H), 5.25 (s, 2H),
4.82 (s, 2H), 2.30 (s, 3H), 1.65 (s, 6H).

Step H: Carboxylic Acid 1-8

15


A solution containing 176 mg (0.492 mmol) of the ester 1-7 from step
G and 50 mg of 10% Pd on carbon in 12 mL of THF and 6 mL of MeOH was
hydrogenated at room temperature under a balloon of H₂. After stirring for 20 min, the
reaction mixture was filtered through Celite and evaporated to dryness to give acid 1-
20 8.

¹H NMR (DMSO d₆) δ 13.2 (bs, 1H), 9.45 (s, 1H), 6.20 (s, 1H), 4.70 (s, 2H), 2.50 (s,
3H), 1.60 (s, 6H).

Compound 1-9

- 5 To a solution of the acid 1-8 from step H (74 mg, 0.28 mmol) and 67 mg (0.30 mmol) of 5-aminomethyl-6-azaindole in 1 mL of DMF was added 59 mg (0.30 mmol) of EDC, 41 mg (0.30 mmol) of HOBT and 0.132 mL of N-methylmorpholine. The reaction mixture was allowed to stir for 16 h before removal of the solvent *in vacuo*. The mixture was diluted with 20 mL of EtOAc and 5 mL
- 10 water. The aqueous phase was discarded and the organic solution was washed with 3 x 5 mL of water then 10 mL of brine. Evaporation of the solvent and recrystallization from ether gave the desired compound 1-9 as a white solid.
- ¹H NMR (DMSO d₆) δ 11.2 (bs, 1H), 9.45 (bs, 1H), 8.75 (bt, 1H), 8.65 (s, 1H), 7.60 (s, 1H), 7.45 (s, 1H), 6.42 (s, 1H), 6.20 (s, 1H), 4.80 (s, 2H), 4.40 (d, 2H), 2.30 (s, 3H), 1.50 (s, 6H).
- 15


The following example shows a detailed procedure for obtaining an amino alcohol corresponding to compound 1-4 which has different substituents for R¹ and R².

EXAMPLE 220 Ketone 2-1

To a -70°C solution of 1.12 g (5.0 mmol) of 3-(N-tert-butoxycarbonylamino)-2-methoxypyridine (Kelly, *Tetrahedron Lett.* 35 (48), 1994,


9003-9006) in 25 mL of dry ether was added 1.8 mL (12.0 mmol) TMEDA followed by 4.8 mL (12.0 mmol) of n-BuLi. The resulting solution was warmed to -15°C where it was aged for 2 h. The reaction mixture was recooled to -70°C and treated with 0.83 mL (7.0 mmol) of ethyl trifluoroacetate. After stirring an additional 3 h, the
5 reaction was quenched with 25 mL of saturated NH₄Cl solution and the two phases were separated. The aqueous phase was extracted with 100 mL of EtOAc and the combined organic extracts were washed with 25 mL of brine and dried over MgSO₄. The yellow solution was concentrated and chromatographed (CH₂Cl₂) to afford trifluoromethyl ketone 2-1.
10 ¹H NMR (CDCl₃) δ 7.95 (d, J=8 Hz, 1H), 7.10 (bs, 1H), 6.95 (d, J=8 Hz, 1H), 4.05 (s, 3H), 1.50 (s, 9H).

Amino ketone 2-2



15

A solution of 320 mg (1.0 mmol) of ketone 2-1 in 30 mL of EtOAc was saturated with gaseous HCl over 5 minutes at 0°C. The reaction mixture was stirred for 1 h then evaporated to dryness. The mixture was redissolved in 50 mL of saturated NaHCO₃ and washed with 3x 50 mL of EtOAc. The yellow solution was
20 concentrated to afford amino ketone 2-2 as a yellow solid.
¹H NMR (CDCl₃) δ 7.90 (d, J=8 Hz, 1H), 6.97 (d, J=8 Hz, 1H), 6.65 (bs, 2H), 3.95 (s, 3H).

Amino alcohol 2-3

- 5 To a -70°C solution of 220 mg (1.0 mmol) of ketone 2-2 in 10 mL of THF was added 8 mL (4.0 mmol) of a 0.5 M ethereal solution of freshly prepared cyclobutylmethylmagnesium bromide. The reaction mixture was stirred to room temperature over 5 h and quenched with 10 mL of saturated NH₄Cl solution. The mixture was extracted with 3 x 50 mL of EtOAc and dried over MgSO₄. Column chromatography (3:2 Hexane / EtOAc) afforded amino alcohol 2-3.
- 10 ¹H NMR (CDCl₃) δ 7.60 (d, J=8 Hz, 1H), 6.60 (d, J=8Hz, 1H), 4.60 (bs, 1H), 3.95 (s, 3H), 2.2-1.6 (m, 10 H).

EXAMPLE 315 Tablet Preparation

 Tablets containing 25.0, 50.0, and 100.0 mg., respectively, of the following active compounds are prepared as illustrated below (compositions A-C). Active I is compound 1-9.

<u>Component</u>	<u>Amount-mg</u>		
	<u>A</u>	<u>B</u>	<u>C</u>
Active I	25	50	100
Micro-crystalline cellulose	37.25	100	200
Modified food corn starch	37.25	4.25	8.5
Magnesium stearate	0.5	0.75	1.5

All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 100.0 mg, respectively, of active ingredient per tablet.

EXAMPLE 4

Tablet Preparation

Exemplary compositions of compound 1-9 tablets are shown below:

Component	0.25 mg	2 mg	10 mg	50 mg
Active I	0.500%	1.000%	5.000%	14.29%
mannitol	49.50%	49.25%	47.25%	42.61%
microcrystalline cellulose	49.50%	49.25%	47.25%	42.61%
magnesium stearate	0.500%	0.500%	0.500%	0.500%

Active I is compound 1-9. 2, 10 and 50 mg tablets were film-coated with an aqueous dispersion of hydroxypropyl cellulose, hydroxypropyl methylcellulose and titanium dioxide, providing a nominal weight gain of 2.4%.

Tablet preparation via direct compression

Active I, mannitol and microcrystalline cellulose were sieved through mesh screens of specified size (generally 250 to 750 μm) and combined in a suitable blender. The mixture was subsequently blended (typically 15 to 30 min) until the drug was uniformly distributed in the resulting dry powder blend. Magnesium stearate was screened and added to the blender, after which a precompression tablet blend was achieved upon additional mixing (typically 2 to 10 min). The precompression tablet blend was then compacted under an applied force, typically ranging from 0.5 to 2.5 metric tons, sufficient to yield tablets of suitable physical strength with acceptable disintegration times (specifications will vary with the size and potency of the compressed tablet). In the case of the 2, 10 and 50 mg potencies, the tablets were dedusted and film-coated with an aqueous dispersion of water-soluble polymers and pigment.

15 Tablet preparation via dry granulation

Alternatively, a dry powder blend is compacted under modest forces and remilled to afford granules of specified particle size. The granules are then mixed with magnesium stearate and tableted as stated above.

20 EXAMPLE 5Intravenous Formulations

Intravenous formulations of compound 1-9 were prepared according to general intravenous formulation procedures. Active I is compound 1-9.

25	<u>Component</u>	<u>Estimated range</u>
	Active I	0.12 - 0.61 mg
	D-glucuronic acid*	0.5 - 5 mg
	Mannitol NF	50-53 mg
	Water for injection	q.s. 1.0 mL

30

1N sodium hydroxide is used to achieve a solution pH in the range of between 3.9-4.1.

Exemplary compositions A-C are as follows:

	<u>Component</u>	<u>A</u>	<u>B</u>	<u>C</u>
5	Active I	0.61 mg*	0.30**	0.15***
	D-glucuronic acid*	1.94 mg	1.94 mg	1.94 mg
	Mannitol NF	51.2 mg	51.2 mg	51.2 mg
	1 N Sodium Hydroxide	q.s. pH 4.0	q.s. pH 4.0	q.s. pH 4.0
	Water for injection	q.s. 1.0 mL	q.s. 1.0 mL	q.s. 1.0 mL

10

* 0.50 mg free base; ** 0.25 mg free base; *** 0.12 mg free base


Various other buffer acids, such as L-lactic acid, acetic acid, citric acid or any pharmaceutically acceptable acid/conjugate base with reasonable buffering capacity in the pH range acceptable for intravenous administration may be substituted

15


for glucuronic acid.

WHAT IS CLAIMED IS:

1. A compound having the formula:



- 5 or a pharmaceutically acceptable salt thereof,
wherein A is



- 10 R^5 is hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, halogen, NH_2 , OH or C_{1-4} alkoxy;
 R^4 is hydrogen, Cl, F, C_{1-4} alkyl or NH_2 ;

Y is hydrogen, Cl, or F;

- 15 R^1 and R^2 are independently
hydrogen,
phenyl, unsubstituted or substituted with one or more of C_{1-4}
alkyl, C_{1-4} alkoxy, halogen, hydroxy, $COOH$, $CONH_2$, CH_2OH ,
 CO_2R^8 , where R^8 is C_{1-4} alkyl, or SO_2NH_2 ,



wherein R^6 and R^7 are independently

hydrogen,

unsubstituted C_{1-4} alkyl,

5 C_{1-4} alkyl substituted with OH, COOH, NH_2 , aryl, CF_3 ,
 C_{3-7} cycloalkyl,

CF_3

$\text{CH}_2\text{C}_{3-7}$ cycloalkyl, unsubstituted or substituted with aryl,



C_{7-12} bicyclic alkyl, or

10 C_{10-16} tricyclic alkyl; and



R^9 is C_{1-4} alkyl or SO_2NH_2 .

2. A compound of claim 1, or a pharmaceutically acceptable salt
 15 thereof, includes those wherein R^4 is Cl, R^5 is hydrogen, and Y is hydrogen.


3. A compound of claim 2, or a pharmaceutically acceptable salt
 thereof, wherein A is



20



, and




5. A pharmaceutical composition comprising a therapeutically
5 effective amount of a compound of Claim 1.

6. A method for inhibiting thrombus formation in blood in a
patient comprising administering to the patient in need thereof a thrombin formation
inhibiting amount of a composition of Claim 5.

10

7. The use of a compound of Claim 1, or a pharmaceutically
acceptable salt thereof, in the manufacture of a medicament for inhibiting thrombin,
inhibiting thrombus formation, treating thrombus formation, or preventing thrombus
formation in a mammal.

8. A compound having the formula:



wherein

5 R^1 and R^2 are independently

hydrogen,

phenyl, unsubstituted or substituted with one or more of C_{1-4}

alkyl, C_{1-4} alkoxy, halogen, hydroxy, $COOH$, $CONH_2$, CH_2OH ,

CO_2R^8 , where R^8 is C_{1-4} alkyl, or SO_2NH_2 ,

10 CHR^6R^7

wherein R^6 and R^7 are independently

hydrogen,

unsubstituted C_{1-4} alkyl,

C_{1-4} alkyl substituted with OH , $COOH$, NH_2 , aryl, CF_3 ,

15 C_{3-7} cycloalkyl,

CF_3

CH_2C_{3-7} cycloalkyl, unsubstituted or substituted with aryl,

C_{7-12} bicyclic alkyl, or

C_{10-16} tricyclic alkyl.

20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/10521

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/5365; C07D 498/04, 519/00

US CL : 514/230.5; 544/91

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/230.5; 544/91

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN/CAS: structure search**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,726,837 A (HAMPRECHT et al.) 23 February 1988 (23.02.1988), column 1, lines 22-38.	1-8



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

22 June 2000 (22.06.2000)

Date of mailing of the international search report

28 JUL 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Richard L. Raymond

Telephone No. (703) 308-1235